The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the ...

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a ...

Moderna Inc. is in discussions with large drugmakers and financial firms to get funding for some late-stage vaccine trials as ...

The Department of Health and Human Services has defended cuts to vaccine research with statements that mislead on the safety ...

The Moderna vaccine is one of the vaccines currently available in the United States and other countries to protect against COVID-19, which is the disease the novel coronavirus causes. Clinical ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

The label expansion for Moderna’s jab arrives at a juncture in America’s changing vaccine regulatory landscape.

The epidemiologist and immunologist Michael Mina called Kennedy’s move a “code red” for vaccines in America. None of the ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include individuals 18-59 years of age who are at increased risk for severe illness from ...

Moderna's shares fell 2.3% on Friday on concerns about whether a new CDC advisory panel would back the use of the company's ...

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...